SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

A strong quarterly report, led by rapid growth in SpaceXs AI compute business and its first profit since its IPO, is driving attention; traders are largely bullish, while some question the valuation and heavy capital spending and flag upcoming share unlocks as a risk.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary fiscal Q1 update raised its revenue and gross-margin outlook well above prior guidance, citing stronger AI-platform demand, and sparked a sharp after-hours rally. Many traders view the update as evidence of robust AI-server demand and see the shares as undervalued, while others question whether the gains will hold given past execution concerns and the stocks volatility.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings beat was overshadowed by softer fourth-quarter guidance, slowing revenue growth and a reduced advertising outlook, prompting a sharp selloff. Traders are debating whether the drop reflects worsening growth prospects or an overreaction to the outlook, with some pointing to continued profitability as a reason to buy the dip.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla and SpaceX have formed committees to explore a potential merger, fueling speculation and bullish reactions; traders also question whether a deal will happen and whether Teslas earnings can support the stocks strength. The merger discussions remain preliminary, with no agreement or certainty of a transaction.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is being swept up in a sharp memory-chip and Korean-market selloff, with traders citing KOSPI weakness, foreign selling, and fears about Chinese competition and the durability of the AI-driven memory cycle. Bulls argue the decline is excessive given strong memory demand and low valuations, while bears see further downside risk from cyclical and oversupply concerns.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads agreement to sell its prenatal-testing business to Labcorp for cash is driving a sharp rally, with bullish traders viewing the proceeds as balance-sheet support and funding for oncology testing. Others question the deal, arguing that shedding a revenue-generating unit could leave a weaker business and persistent debt and execution concerns.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is in focus ahead of its Q3 report, as traders debate whether AI and data-center power demand can support its elevated valuation after a sharp, volatile pullback. Bulls expect results and guidance to validate the growth story, while skeptics point to stretched expectations and broader AI-market pressure as risks.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

The FDAs acceptance of REZZAYOs supplemental application for Priority Review is drawing attention, with traders focused on a possible expansion into invasive-fungal-disease prevention and the pending FDA decision. Optimism about that opportunity is tempered by concerns over DefenCath reimbursement and adoption, management execution, and the stocks muted response to positive developments.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in acute bipolar mania met its primary and secondary endpoints, drawing attention to the drugs potential beyond epilepsy. Traders are divided: bulls view the results as validation of the pipeline, while skeptics point to the modest placebo-adjusted benefit and higher agitation-related side effects and discontinuations as reasons the initial enthusiasm faded.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reported orders from ByteDance, Alibaba, and Tencent for export-compliant Nvidia graphics cards are drawing attention amid U.S. restrictions on more advanced chips. Traders see the orders as evidence of continued Chinese demand, but some are frustrated that the shares have shown little response and question how much Nvidia can deliver given reported supply constraints.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Inhibrx Announces Participation in Upcoming Scientific Conferences

Inhibrx Announces Participation in Upcoming Scientific Conferences Inhibrx Announces Participation in Upcoming Scientific ConferencesPR NewswireSAN DIEGO, Oct. 13, 2026SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage...

Wednesday 9/9 Insider Buying Report: INBX, AMR

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

At Inhibrx Biosciences, a filing with the SEC revealed that on Tuesday, Chief Execu...

Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates

Inhibrx Biosciences reports Phase 2 HexAgon trial data showing improved response rates for INBRX-106 in head and neck cancer.read more...

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study PR Newswire SAN DIEGO, Sept. 8, 2026 First OX40 agonist to...

Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study PR Newswire SAN DIEGO, Sept. 4, 2026 Event to be webcast live...

Inhibrx Reports Second Quarter 2026 Financial Results

Inhibrx Reports Second Quarter 2026 Financial Results Inhibrx Reports Second Quarter 2026 Financial Results PR Newswire SAN DIEGO, Aug. 13, 2026 SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the...

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million PR Newswire SAN DIEGO, July 16, 2026 SAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx...

Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice

Does Inhibrx Biosciences, Inc. (INBX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma PR Newswire SAN DIEGO, June 15, 2026 No filing review issues identified by FDA with PDUFA...

Inhibrx Reports First Quarter 2026 Financial Results

Inhibrx Reports First Quarter 2026 Financial Results Inhibrx Reports First Quarter 2026 Financial Results PR Newswire SAN DIEGO, May 14, 2026 SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx...

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Inhibrx Biosciences Inc.

INBX Stock Hit Record Highs: Cancer Therapies Reportedly Draw Big Pharma Interest

Equity

Bearish Sentiment

<ul><li>The therapy, which is being tested alone and in combination with Keytruda, a prescription immunotherapy, could be valued at over $8 billion, according to the report.</li><li>Inhibrx Biosciences could also spin off INBRX-106, along with another experimental cancer drug, into a separate entity.</li><li>The biotech firm reported promising interim data from its Phase 1/2 trial for advanced colorectal cancer on Tuesday.</li></ul>Shares of Inhibrx Biosciences (INBX) surged more than 40% on Wednesday to an all-time high, following reports of potential deal interest in its cancer pipeline, adding to momentum from encouraging early-stage colorectal cancer trial results.<h2>All Eyes On INBRX-106</h2>According to a Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/world/merck-rivals-eye-deal-inhibrx-experimental-cancer-drug-tied-keytruda-sources-say-2026-04-22/">report</a> on Wednesday,&nbsp;Inhibrx Biosciences has attracted early-stage interest from major drugmakers including Merck &amp; Co. (MRK), and Ono Pharmaceutical, for its experimental drug INBRX-106.The therapy, which is being tested alone and in combination with Keytruda, a prescription immunotherapy, could be valued at over $8 billion if trials confirm its potential to boost treatment response rates.The biotech firm could also spin off INBRX-106, along with another experimental cancer drug, into a separate entity that could be worth over $9 billion if trials are successful.<h2>New Cancer Drug Shows Promise</h2>Meanwhile, its second key asset, Ozekibart, is also gaining traction after Inhibrx Biosciences reported interim Phase 1/2 data for advanced colorectal cancer, showing promising results in pretreated patients.Among 45 patients, the treatment achieved a 20% response rate, well above the typical 1% - 6% seen with standard therapies. Nearly half of these responses lasted more than six months. The median progression-free survival was 5.5 months, and 42% of patients remained progression-free at 6 months.The therapy also showed a manageable safety profile, with mostly mild to moderate side effects such as diarrhea, fatigue, and nausea. Inhibrx plans to meet with the U.S. Food and Drug Administration (FDA) later this year to discuss advancing the treatment into late-stage trials.<h2>INBX Stock: How Did Retail Traders React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/INBX">INBX</a> turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high’ message volumes.One user noted “very strong data” from the Ozekibart trial.<stembedurl>https://stocktwits.com/BullStockpicks1/message/650960093</stembedurl>Another user was bullish about the firm’s prospects.<stembedurl>https://stocktwits.com/Terzman/message/650834526</stembedurl>Year-to-date, the stock has gained around 5%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

Inhibrx Biosciences has attracted early-stage interest from major drugmakers including Merck & Co. and Ono Pharmaceutical, for its experimental drug INBRX-106, according to a Reuters report.

INBX Stock Hit Record Highs: Retail Turns ‘Extremely Bullish’ On This Cancer Play 

Inhibrx Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$95.30
Prev Close	$89.79
Open	$89.07
Dividend Yield	0.00%
50-Day Moving Average	$103.78
Beta	1.20
Avg. Volume	353,779.68
PE Ratio	-10.74

52-Week High	$155.29
52-Week Low	$28.16
Market Capitalization	$1.32B
EPS (Annual)	-$9.04
Price to Book	-26.46
Revenue Per Employee	$11,818.18

Feed

News

Sentiment

Earnings

Fundamentals

Info

INBX Fundamentals